You transfer Chlamydia trachomatis through direct mucosal contact with infected genital secretions, semen, rectal fluid, or eye discharge. The bacterium cannot penetrate intact skin and does not survive long outside the body. Unprotected vaginal, anal, or oral sex is the dominant route, but unwashed hands, shared sex toys, and an infected mother's birth canal also transmit it. Transmission requires a mucosal portal of entry, so intact skin on the fingers is not enough.

The mechanism: how a mucosal bacterium crosses the line

Chlamydia is an obligate intracellular bacterium, meaning it must enter a host cell to replicate. Its infectious form, the elementary body, is metabolically inert and structurally toughened for extracellular travel. Outside a host, that toughness buys it minutes, not days. The organism survives best in the warm, moist environment of mucosal tissue, which is why the cervix, urethra, rectum, and conjunctiva are its preferred landing zones.

Entry begins when an elementary body docks onto a columnar epithelial cell and triggers the cell to engulf it. Inside, it converts to a reticulate body and divides. Roughly 48 to 72 hours later, the cell packs new elementary bodies and ruptures, releasing them to infect neighboring cells. The scales involved explain a lot of transmission biology.

A single infected cell can release hundreds of elementary bodies. That means a very small inoculum can establish an infection. The corollary cuts both ways. It means exposure risk is governed less by visible fluid volume than by whether infected secretions reach a susceptible mucosal surface at all. Semen itself is not the infectious unit so much as the infected cells and elementary bodies it carries from the urethra.

The epithelial preference also explains the portals. The vagina's stratified squamous lining is more resistant than the single-layer columnar cells of the cervix and urethra. In prepubertal girls, the vaginal lining is thinner and less protected, which is one reason non-sexual household transmission is reported more often in that age group. The bacterium is not airborne and does not spread through casual contact like a cold.

Quantified context: how much transmission happens per exposure

Precise per-act transmission probabilities for chlamydia remain unsettled in the literature. Unlike HIV, where per-act estimates are well characterized, chlamydia's short-lived extracellular survival and partly asymptomatic course make exposure studies difficult. What is well established from partner studies and natural-history cohorts is that transmission efficiency is high enough that a single unprotected encounter can suffice, and that repeat exposure compounds risk steeply.

Age is the strongest epidemiologic signal. Reported chlamydia rates in the United States are highest among adolescents and young adults aged 15 to 24, a group that accounts for roughly half of reported cases. That pattern reflects behavioral and biological factors together, since the adolescent cervix has a larger exposed columnar epithelium (ectopy) than the adult cervix. Ectopy regresses with age and hormonal change.

Asymptomatic carriage drives the statistics. Most genital chlamydia infections in women and a large share in men produce no symptoms, so an infected partner often transmits without knowing it. Modeling of partner notification consistently finds that a substantial fraction of sexual contacts of confirmed cases are themselves infected and unaware. The practical number to remember is that "no symptoms" tells you nothing about infectiousness.

Timeline: what happens after exposure and when testing works

Time point What is happening What testing shows
Day 0 Mucosal exposure to elementary bodies Nothing; too early
Days 1-3 Organism enters epithelial cells, begins replicating Nothing reliable
Days 3-7 Incubation period; symptoms, if any, may appear Typically too early for most assays
1-2 weeks Peak window for standard nucleic acid testing Positive results reliable for most people
2-3 weeks Most urogenital infections detectable if present Negative result meaningfully reassuring
Untreated weeks-months Ongoing carriage, often asymptomatic Positive; complications can accrue
After treatment Organism cleared, but re-exposure resets the clock Retest at recommended interval

The incubation window is the operational heart of the timeline. Symptom onset, when it happens at all, usually falls within one to three weeks of exposure. Standard nucleic acid amplification tests are highly sensitive, but a test taken too soon after exposure can read negative before the organism has reached detectable levels. That gap is why guidance generally recommends waiting a couple of weeks after a known exposure before testing, and why a negative test drawn immediately after exposure carries little reassurance.

The same biology governs treatment follow-up. After appropriate therapy, the organism is expected to clear, but re-infection is common when partners are not treated, so retesting at a specified interval rather than immediately is the standard approach.

Edge cases: routes people underestimate

The rectum is an underappreciated site. Chlamydia can infect the rectal mucosa through receptive anal sex, but it can also reach the rectum in people who report only vaginal sex, via secretion spread from the genital tract. That means rectal testing decisions should follow reported sexual practices, not assumptions from anatomy alone.

The throat is a genuinely different story. Oropharyngeal chlamydia from oral sex occurs but is less common and clears more readily than genital infection, and routine throat testing is not generally recommended outside specific contexts. The organism does not transmit efficiently from the throat onward, which limits its epidemiologic weight. The counterintuitive point: oral sex is a real but comparatively minor route.

The eye is a documented mucosal target. Adult inclusion conjunctivitis follows exposure of the conjunctiva to infected genital secretions, most often via contaminated fingers. Neonatal conjunctivitis follows passage through an infected birth canal. This is not the same as trachoma, a separate serovar-driven disease of repeated childhood eye infection.

Fomites get more blame than they deserve. The bacterium's poor extracellular survival makes transmission via toilet seats, towels, and shared surfaces exceedingly unlikely. The exception worth respecting is a sex toy used immediately after contamination, because it delivers fluid directly to a mucosal surface. A moist object used promptly is a plausible vehicle; a dry surface hours later is not.

Misconceptions worth dismantling

Condoms are protective, but not perfectly so. They cover the penis and reduce exposure, yet they can fail to cover infected skin or secretions at the base of the penis, and they do nothing for oral or digital contact with mucosal sites. The consistent finding is that condom use lowers risk substantially without eliminating it. "We used a condom" is risk reduction, not risk elimination.

Withdrawal does not prevent chlamydia. Pre-ejaculate can carry infected urethral secretions. The bacterium lives in the mucosal lining, not only in semen, so removing ejaculate before it arrives misses the point.

Mutual monogamy is protective only if both partners are actually negative. A long-term relationship with an untreated infection is not a shield. The relevant fact is each partner's status, which is why testing, not commitment language, is the operative variable.

Douching, urination after sex, and washing do not prevent infection. These actions occur after exposure has already happened. They may alter the local environment but do not remove organisms that have already entered epithelial cells.

Practical actions: what to do after a possible exposure

Get tested if you have had unprotected sex with a partner of unknown status, a new partner, or a partner with a known infection. Wait roughly two weeks after the exposure for a reliable result unless symptoms prompt earlier evaluation. Test all exposed sites. A urogenital swab or urine test does not detect rectal or throat infection, so tell the clinician what kind of sex you had. Tell partners so they can be tested and treated. Untreated partners are the main source of re-infection. Avoid sex until you and your partners have completed treatment and any recommended retest interval has passed. Use condoms consistently to lower, though not eliminate, transmission risk. Seek prompt care for pelvic pain, discharge, painful urination, rectal pain, or eye redness with discharge.

Red-flag warnings that warrant urgent evaluation:

Fever with pelvic or abdominal pain, which can signal pelvic inflammatory disease. Painful swelling of the testicle, which can accompany epididymitis. Eye redness with pus-like discharge after genital contact. Symptoms in a pregnant person, or a pregnant partner of someone with a recent positive test, given the neonatal risk. Any new genital symptoms after a known exposure, even if mild.

Limitations: what the science cannot yet pin down

Per-act transmission probability for chlamydia remains imprecisely quantified, so any single "chance per encounter" number you encounter should be treated with caution. The literature supports high efficiency and dose-dependent risk, not a precise percentage. Anything claiming exact percentage risk per act is extrapolating beyond the evidence.

Asymptomatic fraction estimates vary by population and testing method, so treat "most infections are silent" as a robust qualitative claim rather than a fixed figure. Site-specific clearance times differ for genital, rectal, and throat infection, and the throat's lower transmissibility is better established than its exact duration.

What is not in doubt is the core mechanism. Transmission requires mucosal contact with infectious secretions, occurs efficiently through sexual routes, and is amplified by asymptomatic carriage and untreated partners. The preventive logic follows directly: barrier protection lowers risk, site-appropriate testing catches silent infection, and partner treatment closes the loop that keeps re-infection going.